Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...

AbbVie will also acquire Nimble's peptide synthesis platform, which is used to discover and optimize oral peptide therapeutics. Roche further taps drug discovery spinout's Nimble tech in $1.1B ...

The molecular machines that Pistofidis and Schmeing studied are called nonribosomal peptide synthetases, or NRPSs. They build some of the most important compounds in current health care and ...